Newsroom

Press Releases

Sparian Biosciences Awarded $19.5 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-226 for Opiate Use Disorder/ Opiate Withdrawal Syndrome Through Phase 1 Clinical Development

November 14, 2024

Sparian Biosciences Announces Formation of its Science Advisory Board

November 13, 2024

Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000

November 12, 2024

Sparian Biosciences Joins U.S. Senate Panel in Fighting Fentanyl

June 5, 2024

Sparian Biosciences Urges U.S. Senate to Support NIH’s Fight Against Substance Abuse

May 23, 2024

Sparian Biosciences Awarded $19 Million Five-Year NIH/NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development

August 8, 2023

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of First-In-Class Arylepoxamide Agonist, SBS-1000, for the Treatment of Pain

February 23, 2023

Sparian Biosciences Announces IND Clearance of First-In-Class Arylepoxamide Agonist, SBS-1000, for the Treatment of Pain by the U.S. FDA

February 9, 2023

Media Contact

Annie Pasternak
Chief Operating Officer
Sparian Biosciences
contact@sparianbiosciences.com

Subscribe to Receive News Alerts

Fill out my online form.